lobbying_activities: 1295820

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1295820	4cf1e53e-c891-43ce-a8b5-2001e65b8973	Q3	HOLLAND & KNIGHT LLP	18466	SHIRE PHARMACEUTICALS, INC	2012	third_quarter	HCR	Drug shortage legislation: Preserving Access to Life-Saving Medications Act (H.R. 2245 and S. 296); Drug Shortage Prevention Act of 2012 (H.R. 3839) to be sure companies in compliance with FDA/DEA rules were not penalized; legislative provisions concerning DEA quotas for controlled substances; manufacturing and distribution process regarding Adderall; dispensing of Adderall products. Lobbied for inclusion of provisions in S. 3187, the Food & Drug Administration Safety & Innovation Act and HR 5651, the Food & Drug Administration Reform Act of 2012. Also worked on provisions in those billes that: provide for accelerated approval, modify FDA Advisory Committee Rules, create a voucher program to incentivize companies to develop products for rare pediatric cancer, and extend enantiomer exclusivity program.	HOUSE OF REPRESENTATIVES,SENATE	40000		0	0	2012-10-08T14:17:38.240000-04:00